Semin Neurol 2011; 31(1): 054-064
DOI: 10.1055/s-0031-1271310
© Thieme Medical Publishers

Seizures: Diagnosis and Management in the Outpatient Setting

Katherine H. Noe1
  • 1Division of Epilepsy, Department of Neurology, Mayo Clinic, Phoenix, Arizona
Further Information

Publication History

Publication Date:
14 February 2011 (online)

ABSTRACT

Epilepsy and seizures are common, and can significantly affect quality of life. A careful history and guided evaluation is necessary to avoid misdiagnosis, to establish causation, and to determine prognosis. Medical therapy is effective in controlling seizures in two thirds of people with epilepsy. In choosing which antiepileptic drug to use, it is important to consider epilepsy type, side effect profile, and cost. Even when seizures are controlled, dose-related side effects from antiepileptic medication, such as fatigue and imbalance, can negatively impact health-related quality of life. Teratogenic side effects are also of concern for women of childbearing age. Monotherapy is generally preferred, and with dose titration, a successful balance between efficacy and tolerability can be reached in the majority of patients. Epilepsy that is medically refractory may respond to epilepsy surgery or vagus nerve stimulation.

REFERENCES

  • 1 Berg A T, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review.  Neurology. 1991;  41 (7) 965-972
  • 2 Annegers J F, Hauser W A, Lee J R, Rocca W A. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935-1984.  Epilepsia. 1995;  36 (4) 327-333
  • 3 Loiseau J, Loiseau P, Guyot M, Duche B, Dartigues J F, Aublet B. Survey of seizure disorders in the French southwest. I. Incidence of epileptic syndromes.  Epilepsia. 1990;  31 (4) 391-396
  • 4 Hauser W A, Annegers J F, Kurland L T. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984.  Epilepsia. 1993;  34 (3) 453-468
  • 5 MacDonald B K, Cockerell O C, Sander J W, Shorvon S D. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK.  Brain. 2000;  123 (Pt 4) 665-676
  • 6 Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorffer D, Kjartansson O, Hauser W A. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study.  Lancet Neurol. 2005;  4 (10) 627-634
  • 7 Loiseau P, Loiseau J, Picot M C. One-year mortality in Bordeaux cohort: the value of syndrome classification.  Epilepsia. 2005;  46 (Suppl 11) 11-14
  • 8 Manford M, Hart Y M, Sander J W, Shorvon S D. National General Practice Study of Epilepsy (NGPSE): partial seizure patterns in a general population.  Neurology. 1992;  42 (10) 1911-1917
  • 9 Camfield C S, Camfield P R. Juvenile myoclonic epilepsy 25 years after seizure onset: a population-based study.  Neurology. 2009;  73 (13) 1041-1045
  • 10 Krumholz A, Wiebe S, Gronseth G Quality Standards Subcommittee of the American Academy of Neurology et al. Practice Parameter: evaluating an apparent unprovoked first seizure in adults (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.  Neurology. 2007;  69 (21) 1996-2007
  • 11 Worrell G A, Lagerlund T D, Buchhalter J R. Role and limitations of routine and ambulatory scalp electroencephalography in diagnosing and managing seizures.  Mayo Clin Proc. 2002;  77 (9) 991-998
  • 12 Benbadis S R. Errors in EEGs and the misdiagnosis of epilepsy: importance, causes, consequences, and proposed remedies.  Epilepsy Behav. 2007;  11 (3) 257-262
  • 13 Wiebe S, Téllez-Zenteno J F, Shapiro M. An evidence-based approach to the first seizure.  Epilepsia. 2008;  49 (Suppl 1) 50-57
  • 14 Bronen R A, Fulbright R K, Spencer D D et al.. Refractory epilepsy: comparison of MR imaging, CT, and histopathologic findings in 117 patients.  Radiology. 1996;  201 (1) 97-105
  • 15 Lawn N D, Bamlet W R, Radhakrishnan K, O'Brien P C, So E L. Injuries due to seizures in persons with epilepsy: a population-based study.  Neurology. 2004;  63 (9) 1565-1570
  • 16 Cockerell O C, Johnson A L, Sander J W, Hart Y M, Goodridge D M, Shorvon S D. Mortality from epilepsy: results from a prospective population-based study.  Lancet. 1994;  344 (8927) 918-921
  • 17 Lindsten H, Nyström L, Forsgren L. Mortality risk in an adult cohort with a newly diagnosed unprovoked epileptic seizure: a population-based study.  Epilepsia. 2000;  41 (11) 1469-1473
  • 18 Lhatoo S D, Johnson A L, Goodridge D M, MacDonald B K, Sander J W, Shorvon S D. Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort.  Ann Neurol. 2001;  49 (3) 336-344
  • 19 Loiseau P, Loiseau J, Picot M C. One-year mortality in Bordeaux cohort: the value of syndrome classification.  Epilepsia. 2005;  46 (Suppl 11) 11-14
  • 20 Annegers J F, Shirts S B, Hauser W A, Kurland L T. Risk of recurrence after an initial unprovoked seizure.  Epilepsia. 1986;  27 (1) 43-50
  • 21 Hauser W A, Anderson V E, Loewenson R B, McRoberts S M. Seizure recurrence after a first unprovoked seizure.  N Engl J Med. 1982;  307 (9) 522-528
  • 22 Kim L G, Johnson T L, Marson A G, Chadwick D W. MRC MESS Study group . Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial.  Lancet Neurol. 2006;  5 (4) 317-322
  • 23 van Donselaar C A, Schimsheimer R J, Geerts A T, Declerck A C. Value of the electroencephalogram in adult patients with untreated idiopathic first seizures.  Arch Neurol. 1992;  49 (3) 231-237
  • 24 Kwan P, Brodie M J. Early identification of refractory epilepsy.  N Engl J Med. 2000;  342 (5) 314-319
  • 25 Cockerell O C, Johnson A L, Sander J W, Shorvon S D. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study.  Epilepsia. 1997;  38 (1) 31-46
  • 26 Mattson R H, Cramer J A, Collins J F et al.. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.  N Engl J Med. 1985;  313 (3) 145-151
  • 27 Mattson R H, Cramer J A, Collins J F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group.  N Engl J Med. 1992;  327 (11) 765-771
  • 28 Brodie M J, Perucca E, Ryvlin P, Ben-Menachem E, Meencke H J. Levetiracetam Monotherapy Study Group . Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.  Neurology. 2007;  68 (6) 402-408
  • 29 Marson A G, Al-Kharusi A M, Alwaidh M SANAD Study group et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.  Lancet. 2007;  369 (9566) 1000-1015
  • 30 Marson A G, Al-Kharusi A M, Alwaidh M SANAD Study group et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.  Lancet. 2007;  369 (9566) 1016-1026
  • 31 Carpay J A, Aldenkamp A P, van Donselaar C A. Complaints associated with the use of antiepileptic drugs: results from a community-based study.  Seizure. 2005;  14 (3) 198-206
  • 32 Harden C L, Meador K J, Pennell P B American Academy of Neurology et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society.  Neurology. 2009;  73 (2) 133-141
  • 33 Meador K J, Reynolds M W, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts.  Epilepsy Res. 2008;  81 (1) 1-13
  • 34 Meador K J, Baker G A, Browning N NEAD Study Group et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.  N Engl J Med. 2009;  360 (16) 1597-1605
  • 35 Vinten J, Bromley R L, Taylor J, Adab N, Kini U, Baker G A. Liverpool and Manchester Neurodevelopment Group . The behavioral consequences of exposure to antiepileptic drugs in utero.  Epilepsy Behav. 2009;  14 (1) 197-201
  • 36 Morrow J I, Hunt S J, Russell A J et al.. Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register.  J Neurol Neurosurg Psychiatry. 2009;  80 (5) 506-511
  • 37 Kjaer D, Horvath-Puhó E, Christensen J et al.. Antiepileptic drug use, folic acid supplementation, and congenital abnormalities: a population-based case-control study.  BJOG. 2008;  115 (1) 98-103
  • 38 MRC Vitamin Study Research Group . Prevention of neural tube defects: results of the Medical Research Council Vitamin Study.  Lancet. 1991;  338 (8760) 131-137
  • 39 Harden C L, Pennell P B, Koppel B S American Academy of Neurology et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society.  Neurology. 2009;  73 (2) 142-149
  • 40 Harden C L, Hopp J, Ting T Y American Academy of Neurology et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society.  Neurology. 2009;  73 (2) 126-132
  • 41 Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels.  Neurology. 2003;  61 (4) 570-571
  • 42 Carpay J A, Aldenkamp A P, van Donselaar C A. Complaints associated with the use of antiepileptic drugs: results from a community-based study.  Seizure. 2005;  14 (3) 198-206
  • 43 Naritoku D K, Hulihan J F, Schwarzman L K, Kamin M, Olson W H. Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial.  Ann Pharmacother. 2005;  39 (3) 418-423
  • 44 Pack A M, Morrell M J, Randall A, McMahon D J, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy.  Neurology. 2008;  70 (18) 1586-1593
  • 45 Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L. Fracture risk is increased in epilepsy.  Acta Neurol Scand. 1999;  99 (5) 269-275
  • 46 Kwan P, Arzimanoglou A, Berg A T et al.. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.  Epilepsia. 2010;  51 (6) 1069-1077
  • 47 Luciano A L, Shorvon S D. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy.  Ann Neurol. 2007;  62 (4) 375-381
  • 48 Callaghan B C, Anand K, Hesdorffer D, Hauser W A, French J A. Likelihood of seizure remission in an adult population with refractory epilepsy.  Ann Neurol. 2007;  62 (4) 382-389
  • 49 Handforth A, DeGiorgio C M, Schachter S C et al.. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial.  Neurology. 1998;  51 (1) 48-55
  • 50 The Vagus Nerve Stimulation Study Group . A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures.  Neurology. 1995;  45 (2) 224-230
  • 51 DeGiorgio C M, Schachter S C, Handforth A et al.. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures.  Epilepsia. 2000;  41 (9) 1195-1200
  • 52 Murphy M, Smith P D, Wood M et al.. Surgery for temporal lobe epilepsy associated with mesial temporal sclerosis in the older patient: a long-term follow-up.  Epilepsia. 2010;  51 (6) 1024-1029
  • 53 Wiebe S, Blume W T, Girvin J P, Eliasziw M. Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group . A randomized, controlled trial of surgery for temporal-lobe epilepsy.  N Engl J Med. 2001;  345 (5) 311-318
  • 54 Engel Jr J, Wiebe S, French J Quality Standards Subcommittee of the American Academy of Neurology et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons.  Neurology. 2003;  60 (4) 538-547
  • 55 Callaghan N, Garrett A, Goggin T. Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study.  N Engl J Med. 1988;  318 (15) 942-946
  • 56 Sillanpää M, Schmidt D. Prognosis of seizure recurrence after stopping antiepileptic drugs in seizure-free patients: A long-term population-based study of childhood-onset epilepsy.  Epilepsy Behav. 2006;  8 (4) 713-719
  • 57 Tennison M, Greenwood R, Lewis D, Thorn M. Discontinuing antiepileptic drugs in children with epilepsy. A comparison of a six-week and a nine-month taper period.  N Engl J Med. 1994;  330 (20) 1407-1410
  • 58 Baker G A, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with epilepsy: a European study.  Epilepsia. 1997;  38 (3) 353-362
  • 59 Gilliam F, Kuzniecky R, Faught E, Black L, Carpenter G, Schrodt R. Patient-validated content of epilepsy-specific quality-of-life measurement.  Epilepsia. 1997;  38 (2) 233-236
  • 60 Jacoby A, Baker G A, Steen N, Potts P, Chadwick D W. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. Community study.  Epilepsia. 1996;  37 (2) 148-161
  • 61 Strine T W, Kobau R, Chapman D P, Thurman D J, Price P, Balluz L S. Psychological distress, comorbidities, and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey.  Epilepsia. 2005;  46 (7) 1133-1139
  • 62 Jones J E, Hermann B P, Barry J J, Gilliam F G, Kanner A M, Meador K J. Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy.  Epilepsy Behav. 2003;  4 (Suppl 3) S31-S38
  • 63 Johnson E K, Jones J E, Seidenberg M, Hermann B P. The relative impact of anxiety, depression, and clinical seizure features on health-related quality of life in epilepsy.  Epilepsia. 2004;  45 (5) 544-550
  • 64 Boylan L S, Flint L A, Labovitz D L, Jackson S C, Starner K, Devinsky O. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy.  Neurology. 2004;  62 (2) 258-261
  • 65 Cramer J A, Blum D, Reed M, Fanning K. Epilepsy Impact Project Group . The influence of comorbid depression on quality of life for people with epilepsy.  Epilepsy Behav. 2003;  4 (5) 515-521
  • 66 Camfield P, Camfield C. Idiopathic generalized epilepsy with generalized tonic-clonic seizures (IGE-GTC): a population-based cohort with > 20 year follow up for medical and social outcome.  Epilepsy Behav. 2010;  18 (1-2) 61-63
  • 67 Shareef Y S, McKinnon J H, Gauthier S M, Noe K H, Sirven J I, Drazkowski J F. Counseling for driving restrictions in epilepsy and other causes of temporary impairment of consciousness: how are we doing?.  Epilepsy Behav. 2009;  14 (3) 550-552

Katherine H NoeM.D. Ph.D. 

Division of Epilepsy, Department of Neurology, Mayo Clinic

5777 East Mayo Boulevard, Phoenix, AZ 85054

Email: noe.katherine@mayo.edu

    >